Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Sodium Acetate

×

Overview

What is Sodum Acetate?

Sodium Acetate for Injection, USP , 4 mEq/mL, is a sterile, nonpyrogenic, concentrated solution of Sodium Acetate (CHNaO) in Water for Injection. It must be diluted prior to administration.

Each 50 mL vial contains 16.4 grams of Sodium Acetate (anhydrous) which provides 200 mEq each of Sodium (Na) and Acetate (CHCOO).

The pH is adjusted with acetic acid and the solution contains no bacteriostatic agent or other preservative.

The solution is intended as an alternative to Sodium Chloride to provide sodium ion (Na) for addition to large volume infusion fluids for intravenous use. Unused portion should be discarded.



What does Sodum Acetate look like?



What are the available doses of Sodum Acetate?

Sorry No records found.

What should I talk to my health care provider before I take Sodum Acetate?

Sorry No records found

How should I use Sodum Acetate?

Sodium Acetate for Injection, USP is indicated as a source of sodium in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas, when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Sodium Acetate for Injection, USP (4 mEq/mL), is administered intravenously only after dilution.

The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluids to provide the desired number of milliequivalents (mEq) of sodium (Na) with an equal number of milliequivalents of acetate (CHCOO).

Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.


What interacts with Sodum Acetate?

Sorry No Records found


What are the warnings of Sodum Acetate?

Sorry No Records found


What are the precautions of Sodum Acetate?

Sorry No Records found


What are the side effects of Sodum Acetate?

Sorry No records found


What should I look out for while using Sodum Acetate?

Sodium Acetate for Injection, USP is contraindicated in patients with HYPERNATREMIA.

Sodium Acetate for Injection, USP must be diluted before use. To avoid sodium overload and water retention, infuse sodium containing solutions slowly. Do not use unless solution is clear and seal is intact.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.


What might happen if I take too much Sodum Acetate?

Sorry No Records found


How should I store and handle Sodum Acetate?

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Sodium Acetate for Injection, USP (4 mEq /mL)NDC 0517-5023-25     50 mL Single Dose Vial     packed in boxes of 25Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) (See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN5023Rev. 11/05Sodium Acetate for Injection, USP (4 mEq /mL)NDC 0517-5023-25     50 mL Single Dose Vial     packed in boxes of 25Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) (See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN5023Rev. 11/05Sodium Acetate for Injection, USP (4 mEq /mL)NDC 0517-5023-25     50 mL Single Dose Vial     packed in boxes of 25Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) (See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN5023Rev. 11/05Sodium Acetate for Injection, USP (4 mEq /mL)NDC 0517-5023-25     50 mL Single Dose Vial     packed in boxes of 25Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) (See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN5023Rev. 11/05Sodium Acetate for Injection, USP (4 mEq /mL)NDC 0517-5023-25     50 mL Single Dose Vial     packed in boxes of 25Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) (See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN5023Rev. 11/05Sodium Acetate for Injection, USP (4 mEq /mL)NDC 0517-5023-25     50 mL Single Dose Vial     packed in boxes of 25Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) (See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN5023Rev. 11/05Sodium Acetate for Injection, USP (4 mEq /mL)NDC 0517-5023-25     50 mL Single Dose Vial     packed in boxes of 25Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) (See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN5023Rev. 11/05


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Sodium is the principal cation of extracellular fluids. The sodium ion exerts a primary role in controlling total body water and its distribution. The acetate ion is completely metabolized in the body, providing a source of hydrogen ion acceptors.

Non-Clinical Toxicology
Sodium Acetate for Injection, USP is contraindicated in patients with HYPERNATREMIA.

Sodium Acetate for Injection, USP must be diluted before use. To avoid sodium overload and water retention, infuse sodium containing solutions slowly. Do not use unless solution is clear and seal is intact.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Sodium replacement therapy should be guided primarily by serum sodium level. Use with caution in patients with renal impairment, cirrhosis, cardiac failure or other edematous or sodium retaining states.

Sodium overload can occur with intravenous infusion of excessive amounts of sodium containing compounds. See .

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).